Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders

Perrone, Maria Grazia; Centonze, Antonella; Miciaccia, Morena; Ferorelli, Savina; Scilimati, Antonio

doi:10.3390/molecules25225388

Cited by 17 publications

(12 citation statements)

References 208 publications

(295 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This concluded that celecoxib had great potential to act as a treatment for this mental disorder, with its safety and benefits quite promising [ 182 ]. Another meta-analysis on inflammation-related treatment procedures found that such methods positively affected depression and depressive symptoms treatment [ 185 ]. Collectively, these studies assert that COX-2 inhibitors positively influence the treatment of depression, particularly celecoxib.…”

Section: Current Drug Researchmentioning

confidence: 99%

Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review

Frank

Gruenbaum

Zlotnik

et al. 2022

IJMS

View full text Add to dashboard Cite

Post-stroke depression (PSD) is a biopsychosocial disorder that affects individuals who have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among stroke survivors. Its effects are usually adverse, can lead to disability, and may increase mortality if not managed or treated early. PSD is linked to several other medical conditions, including anxiety, hyper-locomotor activity, and poor functional recovery. Despite significant awareness of its adverse impacts, understanding the pathogenesis of PSD has proved challenging. The exact pathophysiology of PSD is unknown, yet its complexity has been definitively shown, involving mechanisms such as dysfunction of monoamine, the glutamatergic systems, the gut-brain axis, and neuroinflammation. The current effectiveness of PSD treatment is about 30–40 percent of all cases. In this review, we examined different pathophysiological mechanisms and current pharmacological and non-pharmacological approaches for the treatment of PSD.

show abstract

Section: Current Drug Researchmentioning

confidence: 99%

Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review

Frank

Gruenbaum

Zlotnik

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that the therapeutic effects of psychotropic drugs, including mood stabilizers, antidepressants and antipsychotics exhibit, among others, anti-inflammatory properties [ 18 , 19 , 20 , 21 , 22 ]. Consistently, typical anti-inflammatory medications were observed as beneficial in clinical trials researching mood disorders [ 3 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ].…”

Section: Introductionmentioning

confidence: 76%

Low-Dose Aspirin Augments the Anti-Inflammatory Effects of Low-Dose Lithium in Lipopolysaccharide-Treated Rats

et al. 2022

View full text Add to dashboard Cite

Mounting evidence suggests that immune-system dysfunction and inflammation play a role in the pathophysiology and treatment of mood-disorders in general and of bipolar disorder in particular. The current study examined the effects of chronic low-dose aspirin and low-dose lithium (Li) treatment on plasma and brain interleukin-6 and tumor necrosis factor-α production in lipopolysaccharide (LPS)-treated rats. Rats were fed regular or Li-containing food (0.1%) for six weeks. Low-dose aspirin (1 mg/kg) was administered alone or together with Li. On days 21 and 42 rats were injected with 1 mg/kg LPS or saline. Two h later body temperature was measured and rats were sacrificed. Blood samples, the frontal-cortex, hippocampus, and the hypothalamus were extracted. To assess the therapeutic potential of the combined treatment, rats were administered the same Li + aspirin protocol without LPS. We found that the chronic combined treatment attenuated LPS-induced hypothermia and significantly reduced plasma and brain cytokine level elevation, implicating the potential neuroinflammatory diminution purportedly present among the mentally ill. The combined treatment also significantly decreased immobility time and increased struggling time in the forced swim test, suggestive of an antidepressant-like effect. This preclinical evidence provides a potential approach for treating inflammation-related mental illness.

show abstract

“…Consistently, evidence indicates that psychotropic drugs exert a variety of anti-inflammatory effects [17,49,[66][67][68][69][70][71][72][73][74] which may contribute to their therapeutic efficacy. Accordingly, anti-inflammatory drugs such as corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the severity of symptoms among psychiatric patients [45,47,48,[75][76][77][78][79][80][81][82][83].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Combined Low-Dose Lithium and Low-Dose Aspirin: A Pharmacological and Behavioral Proof-of-Concept Study in Rats

et al. 2021

View full text Add to dashboard Cite

Despite established efficacy in bipolar disorder patients, lithium (Li) therapy has serious side effects, particularly chronic kidney disease. We examined the safety and behavioral effects of combined chronic low-dose aspirin plus low-dose Li in rats to explore the toxicity and therapeutic potential of this treatment. Rats were fed regular or Li-containing food (0.1% [low-dose, LLD-Li] or 0.2% [standard-dose, STD-Li]) for six weeks. Low-dose aspirin (1 mg/kg) was administered alone or together with Li. Renal function and gastric mucosal integrity were assessed. The effects of the combination treatment were evaluated in depression-like and anxiety-like behavioral models. Co-treatment with aspirin did not alter plasma Li levels. Chronic STD-Li treatment resulted in significant polyuria and polydipsia, elevated blood levels of creatinine and cystatin C, and increased levels of kidney nephrin and podocin—all suggestive of impaired renal function. Aspirin co-treatment significantly damped STD-Li-induced impairments in kidney parameters. There were no gastric ulcers or blood loss in any treatment group. Combined aspirin and LLD-Li resulted in a significant increase in sucrose consumption, and in the time spent in the open arms of an elevated plus-maze compared with the LLD-Li only group, suggestive of antidepressant-like and anxiolytic-like effects, respectively. Thus, we demonstrate that low-dose aspirin mitigated the typical renal side effects of STD-Li dose and enhanced the beneficial behavioral effects of LLD-Li therapy without aggravating its toxicity.

show abstract

Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders

Cited by 17 publications

References 208 publications

Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review

Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review

Low-Dose Aspirin Augments the Anti-Inflammatory Effects of Low-Dose Lithium in Lipopolysaccharide-Treated Rats

Safety and Efficacy of Combined Low-Dose Lithium and Low-Dose Aspirin: A Pharmacological and Behavioral Proof-of-Concept Study in Rats

Contact Info

Product

Resources

About